---
document_datetime: 2024-06-21 11:23:14
document_pages: 20
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/prialt-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: prialt-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 13.3545
conversion_datetime: 2025-12-20 11:47:53.102738
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Prialt

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0077/G            | This was an application for a group of variations. | 20/06/2024                          |                                             | SmPC                             |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | protocol - Administrative change - Deletion of sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                 | stability A.7 manufacturing   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|-------------------------------|
| IA/0078   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/05/2024 | n/a |                 |                               |
| IAIN/0075 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 18/10/2023 |     | Annex II and PL |                               |
| N/0074    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/10/2022 |     | PL              |                               |
| IA/0073/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or | 17/10/2022 | n/a |                 |                               |

<div style=\"page-break-after: always\"></div>

|                    | starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0072/G          | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.c.z - Container closure system of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 17/10/2022 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/3142/ 202112 | Periodic Safety Update EU Single assessment - ziconotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 01/09/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0068            | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 23/06/2022 | 02/08/2022 | SmPC, Annex II, Labelling and PL | Increasing evidence based on case reports and observational studies show that ziconotide has a better tolerance profile and provides higher benefits when used carefully with low initiation dose and slow titration using low dose increments in long intervals along with continuous monitoring of drug response. As the result, the SmPC was updated to introduce a reduced posology to allow dosing flexibility and meet individual patients' needs in terms of |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        | analgesia and adverse events. Moreover, additional risk minimization measures were implemented in the SmPC/PIL due to serious adverse events, including suicide, that can also occur with low starting doses. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0071/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 08/06/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                               |
| IAIN/0069 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                     | 24/11/2021 | 04/07/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                               |
| IAIN/0067 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                         | 09/06/2021 | 04/07/2022 | Annex II and PL        |                                                                                                                                                                                                                                                                                               |
| N/0065    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                               | 05/10/2020 | 04/07/2022 | PL                     |                                                                                                                                                                                                                                                                                               |
| IA/0066   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                            | 18/08/2020 | n/a        |                        |                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |    |                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------------|
| IA/0064/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 03/04/2020 | n/a        |    | changes to an approved |
| N/0063    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/02/2020 | 04/07/2022 | PL |                        |
| IB/0062/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/02/2020 | n/a        |    |                        |

<div style=\"page-break-after: always\"></div>

| intermediate used in manufacturer of a A.4 - Administrative and/or address of a or supplier of the AS, intermediate used in manufacturer of a A.7 - Administrative manufacturing sites B.I.b.1.c - Change in and/or limits of an specification corresponding test B.I.b.1.z - Change in and/or limits of an B.I.b.2.a - Change in starting changes to an B.I.b.2.a - Change in starting changes to an B.I.b.2.a - Change in starting changes to an B.I.b.2.a - Change in starting changes to an B.I.b.2.a - Change in starting material/reagent/intermediate   | the novel change manufacturer starting the novel change the AS, starting material/intermediate/reagent parameter method the AS, starting material/intermediate/reagent test material/reagent/intermediate approved test material/reagent/intermediate approved test material/reagent/intermediate approved test material/reagent/intermediate approved test   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.d.z - Stability of AS - Other variation   |            |     |                     |               |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------|---------------|
| PSUSA/3142/ 201812 | Periodic Safety Update EU Single assessment - ziconotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/07/2019 | n/a | PRAC Recommendation | - maintenance |
| IA/0061            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/05/2019 | n/a |                     |               |
| IAIN/0060/G        | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.2.c.1 - Change to importer, batch release                                                                                                                                                                                                                                                                                         | 16/05/2019 | n/a |                     |               |

<div style=\"page-break-after: always\"></div>

|             | or addition of a manufacturer for importation and/or batch release - including batch control/testing                                                                                                                                                                                                                   |            |            |                        | Replacement responsible Not   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------|
| IAIN/0059/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                         | 08/04/2019 | 18/12/2019 | Annex II and PL        | site                          |
| IAIN/0057   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                 | 16/01/2019 | 18/12/2019 | Annex II and PL        |                               |
| T/0056      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                    | 08/06/2018 | 02/07/2018 | SmPC, Labelling and PL |                               |
| IA/0055/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place to importer, batch release | 02/05/2018 | n/a        |                        | B.II.b.2.a - Change           |

<div style=\"page-break-after: always\"></div>

|           | of a site where batch takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | Replacement/addition control/testing   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------|
| N/0054    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/11/2017 | 15/01/2018 | PL          |                                        |
| IA/0053/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 24/03/2017 | n/a        |             |                                        |
| II/0052   | Update of sections 4.4 and 4.8 of the SmPC in order to amend the information on anaphylactic reactions following post-marketing cases and the relevant PRAC recommendation in conclusion to the assessment of EMEA/H/C/PSUSA/00003142/201512. The Package Leaflet is updated accordingly. Minor additional changes are made to the SmPC. Change(s) in the SPC, Labelling or PL                                                                                                                                                                                                                                                                    | 26/01/2017 | 15/01/2018 | SmPC and PL | C.I.3.b -                              |

<div style=\"page-break-after: always\"></div>

|                    | intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                                   |            |            |    |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| II/0050            | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                       | 10/11/2016 | n/a        |    |                                   |
| IB/0051/G          | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation | 14/09/2016 | n/a        |    |                                   |
| PSUSA/3142/ 201512 | Periodic Safety Update EU Single assessment - ziconotide                                                                                                                                                                                                                 | 07/07/2016 | n/a        |    | PRAC Recommendation - maintenance |
| N/0048             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                         | 27/01/2016 | 15/01/2018 | PL |                                   |
| IA/0047            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                               | 12/11/2015 | n/a        |    |                                   |
| PSUSA/3142/ 201412 | Periodic Safety Update EU Single assessment - ziconotide                                                                                                                                                                                                                 | 09/07/2015 | n/a        |    | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| R/0045    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/07/2014   | 18/09/2014   | SmPC, Annex II, Labelling and PL   | The benefit -risk balance for Prialt remains unchanged. Minor updates to the product information to bring it in line with the QRD template were introduced. The renewal is granted with unlimited validity.                                                                                                                                                                                                                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0044 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/07/2014   | n/a          |                                    | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                 |
| S/0040    | 8th Annual Re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 21/11/2013   | 17/01/2014   | SmPC, Annex II and PL              | Having reviewed the evidence of compliance with the specific obligations and the data submitted within this annual re-assessment, the CHMP concluded that the benefit risk balance of Prialt in the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia remains positive. As all remaining Specific Obligations were fulfilled, the CHMP agreed that exceptional circumstances should be lifted. |
| IB/0043/G | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.4.b - Change in the batch size (including batch | 10/01/2014   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | down to 10-fold B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products   |            |            |                                  |                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0345   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 03/09/2013 | n/a        |                                  |                                                                                                                                                                                                                                   |
| IAIN/0041 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 21/05/2013 | n/a        |                                  |                                                                                                                                                                                                                                   |
| IB/0039   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 27/03/2013 | 17/01/2014 | SmPC                             |                                                                                                                                                                                                                                   |
| S/0038    | 7th Annual Re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/07/2012 | 20/09/2012 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             | product remains favourable.                                                                                                                                                                                                                                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0037/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding | 15/12/2011 | n/a        |             |                                                                                                                                                                                                                                                               |
| S/0034    | Annual Re-assessment                                                                                                                                                                                                                                                                                                                                                                               | 21/07/2011 | 27/07/2011 |             | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. |
| IB/0036   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                         | 21/07/2011 | n/a        | SmPC and PL |                                                                                                                                                                                                                                                               |
| IA/0035   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                 | 08/06/2011 | n/a        |             |                                                                                                                                                                                                                                                               |
| II/0033   | Change of the vial stoper B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative                                                                                                                                                                                                                                                                      | 23/09/2010 | 28/09/2010 |             |                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|        | composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                                                                                                                          |            |            |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0032 | The CHMP, having reviewed the evidence of compliance with the specific obligations and the safety information submitted by the Marketing Authorisation Holder, concludes that the benefit/risk ratio for the product remains unchanged. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstances in view of the pending specific obligation. | 22/07/2010 | 28/07/2010 |                  | The CHMP, having reviewed the evidence of compliance with the specific obligations and the safety information submitted by the Marketing Authorisation Holder, concludes that the benefit/risk ratio for the product remains unchanged. The CHMP adopted on 22 July 2010 an Opinion on the annual reassessment of Prialt. A new follow-up measure was agreed upon and the Marketing Authorisation Holder provided a revised Letter of Undertaking dated 9 July 2010 detailing the specific obligation and follow-up measures remaining outstanding. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstances in view of the pending specific obligation. |
| N/0031 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                  | 14/04/2010 | n/a        | Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| R/0030 | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                           | 22/10/2009 | 12/01/2010 | SmPC             | Based on the data that have become available since the granting of the marketing authorization under exceptional circumstances, the CHMP considers that the benefit-risk balance of Prialt remains positive, but considers that its safety profile is to be closely monitored for the following reasons: There is one specific obligation outstanding, the PRIME study which is expected to generate relevant long-term                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            |                        | safety and efficacy data on the product. The CHMP is also of the opinion that submission of yearly PSURs should continue until concerns identified in relation to the pharmacovigilance system are adequately addressed. Therefore, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.          |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0029  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 17/09/2009 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                |
| S/0027  | Annual Reassessment                                                                              | 23/04/2009 | 30/04/2009 |                        |                                                                                                                                                                                                                                                                                                                                                |
| IA/0028 | IA_01_Change in the name and/or address of the marketing authorisation holder                    | 17/03/2009 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                |
| IA/0026 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing | 13/02/2009 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                |
| N/0025  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 12/02/2009 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                                                |
| S/0021  | Third Annual Reassessment (S/0021)                                                               | 30/05/2008 | 25/08/2008 | SmPC, Annex II and PL  | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile for Prialt, concluded that the benefit/risk of the product remains unchanged. The CHMP considered that the Marketing Authorisation for Prialt should remain |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            |                            | under exceptional circumstances in view of the pending Specific Obligation.                                                                                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                         | 03/07/2008 | n/a        |                            |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0023 | IA_09_Deletion of manufacturing site                                                             | 24/06/2008 | n/a        |                            |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0022 | IB_37_a_Change in the specification of the finished product - tightening of specification limits | 20/05/2008 | n/a        |                            |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0020 | IA_13_a_Change in test proc. for active substance - minor change                                 | 19/03/2008 | n/a        |                            |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0019 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                       | 15/02/2008 | n/a        | Annex II and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| N/0017  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 21/01/2008 | n/a        | Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0018 | IA_05_Change in the name and/or address of a manufacturer of the finished product                | 28/11/2007 | n/a        |                            |                                                                                                                                                                                                                                                                                                                                                                                                                            |
| S/0009  | Annual re-assessment.                                                                            | 24/05/2007 | 20/07/2007 | Annex II, Labelling and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile for Prialt, concluded that the benefit/risk of the product remains unchanged. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstances in view of the pending Specific Obligation. |

<div style=\"page-break-after: always\"></div>

| IA/0015   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                | 04/07/2007   | n/a        |                        |                                                                                                               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------|
| IA/0014   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                | 04/07/2007   | n/a        |                        |                                                                                                               |
| IB/0010   | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition) IB_38_c_Change in test procedure of finished product - other changes | 03/07/2007   | n/a        |                        |                                                                                                               |
| IA/0016   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                | 02/07/2007   | n/a        |                        |                                                                                                               |
| IA/0013   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                | 02/07/2007   | n/a        |                        |                                                                                                               |
| IA/0012   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                | 18/06/2007   | n/a        |                        |                                                                                                               |
| IA/0011   | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                | 18/06/2007   | n/a        |                        |                                                                                                               |
| IA/0008   | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                              | 06/10/2006   | n/a        | Annex II and PL        |                                                                                                               |
| T/0007    | Transfer of Marketing Authorisation                                                                                                                           | 14/08/2006   | 13/09/2006 | SmPC, Labelling and PL | The Marketing Authorisation has been transferred from Elan Pharma International Ltd to Eisai Limited.         |
| S/0005    | Annual re-assessment.                                                                                                                                         | 01/06/2006   | 28/07/2006 | Annex II               | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                |            |            |             | Authorisation Holder and having re-assessed the benefit/risk profile for Prialt, concluded that the benefit/risk of the product remains favourable in the approved indication. The CHMP considered that the Marketing Authorisation for Prialt should remain under exceptional circumstanced in view of the pending Specific Obligations. (Post Marketing observational study to evaluate the long- term efficacy and safety of Prialt).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004 | This variation refers to an update of the section 4.8 of the Summary of Product Characteristics (SPC) and section 4 of the Package Leaflet (PL) further to the fulfillment of the Follow-Up Measures (FUMs) 004, 005 and 006. Update of Summary of Product Characteristics and Package Leaflet | 27/04/2006 | 31/05/2006 | SmPC and PL | The Marketing Authorisation Holder fulfilled the following Follow-up Measures: - FUM 004: \"To evaluate the potential development of hyperalgesia following IT administration of ziconotide in the controlled studies (95-001, 96-002 and 301).\" - FUM 005: \"To integrate the safety data from studies 301, 302, 351 and 352 into the MAA safety data base, and to look at the adverse events in patients taking CNS active drugs.\" - FUM 006: \"To provide efficacy and safety data on the ongoing long-term studies 351, 352 and 501, including the VASPI scores. To establish the correlations between dose increment intervals and efficacy and safety events.\" Further to the final report analysis on the clinical studies 301, 302, 351, 352 and 501, the MAH applied for an update of the sections 4.8 of the SPC and 4 of the Package Leaflet to reflect the clinical data available on the evaluations of the potential development of hyperalgesia following IT administration of ziconotide in some controlled studies and of the efficacy and safety data on the ongoing long-term studies 351, 352 and 501; the sections 4.8 of the SPC and 4 of the PL were therefore amended according to the adverse event pattern reported in studies 302, 351, |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  | 352 and 501.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0006 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/05/2006 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0003 | This variation relates to an update of sections 4.4, 4.5 and 5.1 of the Summary of Product Characteristics (SPC) to include data from the titration and extension phases of the clinical studies ELN92045-201 and ELN92045-202. The MAH also took this opportunity to include the ATC code in the section 5.1 of the SPC, and to include minor linguistic changes and punctuation errors in the Labelling and Package Leaflet. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 23/02/2006 | 29/03/2006 | SmPC, Labelling and PL           | The Marketing Authorisation Holder has committed to fulfil the following Follow-up Measure: \"To provide the results of formal intrathecal morphine-ziconotide clinical interaction studies (ELN92045-201, ELN92045-202) and submission of a variation to the SPC to account for conclusions from these studies.\" Further to the final report analysis on the long- term extensions of both studies ELN92045-201 and ELN92045-202, the MAH applied for an update of the sections 4.4, 4.5 and 5.1 of the SPC to reflect the clinical data available on concomitant use of IT opioids and IT ziconotide. The MAH also took this opportunity to include the ATC code in the section 5.1 of the SPC. Minor linguistic changes and punctuation errors in the Labelling and Package Leaflet were also made during this procedure. |
| X/0002  | Change or addition of a new strength/potencyAddition of new strength - 25 mg/ml solution for infusion. Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                          | 26/01/2006 | 20/03/2006 | SmPC, Annex II, Labelling and PL | The new presentation consists in one new strength (25 g/ml of ziconotide (as acetate salt), solution for infusion), presented in 20 ml vials. The important quality characteristics of the active substance are well-defined and controlled, and the product is formulated, manufactured and controlled in a way that is characteristic for this new strength application. The specifications and batch analytical results indicate a consistent product with uniform clinical performance from batch to batch. The risk/benefit is considered acceptable since the proposed 25 g/ml solution for infusion is better adapted to the dosing regime and eliminates the need for dilution prior to administration. Apart from the strength, the product is identical to the                                                  |

<div style=\"page-break-after: always\"></div>

|         |                                                                                             |            |     | approved 100 g/ml formulation.   |
|---------|---------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0001 | IA_28_Change in any part of primary packaging material not in contact with finished product | 11/05/2005 | n/a |                                   |